Related Experiment Video
Updated: Mar 26, 2026
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
Recombinant CP40 from Corynebacterium pseudotuberculosis confers protection in mice after challenge with a virulent
Daniela Droppa-Almeida1, Wanessa L P Vivas1, Katharina Kelly O Silva1
1Instituto de Tecnologia e Pesquisa - Universidade Tiradentes, Avenida Murilo Dantas, 300, Farolândia, Aracaju, Sergipe 49032-490, Brazil.
Background:
Caseous Lymphadenitis (CLA) is a contagious, infectious, chronic disease caused by Corynebacterium pseudotuberculosis, which affects mainly sheep and goats. The clinical prevalence of CLA in Brazil is 30%, resulting in decreased milk production, weight loss, and unusable meat and leather. Prophylaxis is based on vaccination; however, current vaccinations do not offer effective protection against the infection, which makes the development of a new vaccine essential to control this disease.
Experimental Approach:
Here, we developed a recombinant vaccine based on CP40 protein (rCP40) combined with an adjuvant (Freund's complete adjuvant or saponin) and evaluated its efficacy in a murine model of CLA. Female BALB/c mice were used in an immunization assay.
Key Results:
rCP40 induced high levels of IgG2a and IgG2b antibodies. After challenge with a virulent strain of C. pseudotuberculosis C57 (10(4)CFU/mL), the levels of IgG2a and IgG2b were sustained, indicating a Th1 response. The groups immunized with rCP40 protein (GES and GEF groups) showed 100% protection and was statistically significant in the GES and GEF groups (p<0.037 and p<0.0952, respectively).
Conclusions:
The results indicated the recombinant protein CP40 induced an specific immune response in mice that was able to afford protection after challenge, regardless the adjuvant used in the formulation.
More Related Videos
06:57Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
Published on: May 12, 2023
08:52Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019